@article {Chhatwal2021.08.11.21261845, author = {Jagpreet Chhatwal and Yingying Xiao and Peter Mueller and Madeline Adee and Ozden O Dalgic and Mary Ann Ladd and Turgay Ayer and Benjamin P Linas}, title = {Changing Dynamics of COVID-19 in the U.S. with the Emergence of the Delta Variant: Projections of the COVID-19 Simulator}, elocation-id = {2021.08.11.21261845}, year = {2021}, doi = {10.1101/2021.08.11.21261845}, publisher = {Cold Spring Harbor Laboratory Press}, abstract = {With the recent emergence of the B.1.617.2 (Delta) variant of SARS-CoV-2 in the U.S., many states are seeing rising cases and hospitalizations after a period of steady decline. As We used the COVID-19 Simulator, an interactive online tool that utilizes a validated mathematical model, to simulate the trajectory of COVID-19 at the state level in the U.S. COVID-19 Simulator{\textquoteright}s forecasts are updated weekly and included in the Centers for Disease Control and Prevention (CDC) ensemble model. We employed our model to analyze scenarios where the Delta variant becomes dominant in every state.The combination of high transmissibility of the Delta variant, low vaccination coverage in several regions, and more relaxed attitude towards social distancing is expected to result in as surge in COVID-19 deaths in at least 40 states. In several states {\textendash} including Idaho, Maine, Montana, Nebraska, North Carolina, Oregon, Puerto Rico, Washington, and West Virginia {\textendash} the projected daily deaths in 2021 could exceed the prior peak daily deaths under current social distancing behavior and vaccination rate. The number of COVID-19 deaths across the U.S. could exceed 1600 per day.Between August 1, 2021, and December 31, 2021, there could be additional 157,000 COVID-19 deaths across the U.S. Of note, our model projected approximately 20,700 COVID-19 deaths in Texas, 16,000 in California, 12,400 in Florida, 12,000 in North Carolina, and 9,300 in Georgia during this period. In contrast, the projected number of COVID-19 deaths would remain below 200 in New Jersey, Massachusetts, Connecticut, Vermont, and Rhode Island.We project COVID-19 deaths based on the current vaccination rates and social distancing behavior. Our hope is that the findings of this report serve a warning sign and people revert to wearing masks and maintain social distancing to reduce COVID-19 associated deaths in the U.S. Our projections are updated weekly by incorporating vaccination rates and social distancing measures in each state; the latest results can be found at the COVID-19 Simulator website.Competing Interest StatementThis research is funded by the Rockefeller Foundation grant to support the work of the Society for Medical Decision Making COVID-19 Decision Modeling Initiative, and National Science Foundation awards 2035360 and 2035361. The funding agreement ensured the authors{\textquoteright} independence in designing the study, interpreting the data, writing, and publishing the report. Drs. Chhatwal and Ayer serve as partners of Value Analytics Labs, a healthcare analytics consulting firm that provides services to pharmaceutical and diagnostic companies. Funding StatementThis research is funded by the Rockefeller Foundation grant to support the work of the Society for Medical Decision Making COVID-19 Decision Modeling Initiative, and National Science Foundation awards 2035360 and 2035361.The funding agreement ensured the independence of authors in designing the study, interpreting the data, writing, and publishing the report.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All data used in this study were publicly available and therefore did not require approval from an institutional review boardAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesOur model is available to the public at www.covid19sim.org and data can be downloaded from the website. https://covid19sim.org/}, URL = {https://www.medrxiv.org/content/early/2021/08/13/2021.08.11.21261845}, eprint = {https://www.medrxiv.org/content/early/2021/08/13/2021.08.11.21261845.full.pdf}, journal = {medRxiv} }